... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Malignant melanoma Sarcopenia Survival Toxicity Sarcopenia plays an important role in oncology. There is great evidence based on large meta-analyses...

... of malignant melanoma (MM) through a systematic review and meta-analysis. Methods: The PubMed and EMBASE databases, from the earliest available date of indexing through December 31, 2018, were searched for studies evaluating the diagnostic performance of 18 F-FDG-PET or PET/CT for the detection of recurrent...

...S. Pyrhönen; M. Kouri; L.R. Holsti; K. Cantell Thirty-one patients, 13 males and 18 females, with metastatic malignant melanoma were treated with human leukocyte interferon (IFN) alpha. The dose was 3 x 10 6 IU daily s.c. for 6 weeks followed by 6 x 10 6 IU/day 3 times a week. Only 1 patient (3...

...William D. Queen; Noor Bharwani; Elizabeth A. Phillips; Ben A. Ruether; Terry M. Phillips; Martin Jerry Circulating immune complexes (CIC) in human cancer are known to be very heterogeneous in size and composition. In 95 staged malignant melanoma patients and 71 individuals with leukemia...

...N. Bharwani; L. Campbell; P. Ashley; W.D. Queen; T.M. Phillips; L.M. Jerry We evaluated the ability of repeated measurements of circulating immune complexes (CIC) to predict for tumor recurrence in 130 patients with malignant melanoma. Twenty-two patients had level 2, 45 had level 3, and 51 had...

...L.M. Hove; L.A. Akslen; F. Hartveit The rising incidence of malignant melanoma is associated with a change in the stage at presentation. As a result more deaths can now be expected in stage I patients, despite their overall better prognosis. More accurate staging, with regional node dissection...

...R. Kuzmits; E.M. Kokoschka; M. Micksche; H. Ludwig; R. Flener There is as yet no effective treatment for renal cell carcinoma and metastasizing malignant melanoma. This fact, coupled with in vitro investigations showing growth inhibitory or cytotoxic effects of interferon (IFN) on renal cell...

.... Malignant melanoma Lymphocyte subpopulations DR antigens Oncology 42: 18-25 (1985) ( 1985 S. Kjirgcr A G . Basel 0030-2414 85 0421 0018 $ 2.75/0 Circulating Lymphocytes Bearing DR Antigens in Human Melanoma L. Marlin Jerry, Mary E. Shea Oncology Research Group, University of Calgary, and ihe Tom Baker...

...N.H. Mulder; J.M. Smit; W.M.I. Kreumer; J. Bouman; D.T. Sleijfer; W. Veeger; Schraffordt Koops The effect of combination chemotherapy (bleomycin, actinomycin D, vindesine and DTIC) on taste sensation in patients with malignant melanoma was evaluated. Five concentrations of 4 basic tastes (sweet...

...T.A. Luger; W. Linkesch; R. Knobler; E.M. Kokoschka In a pilot study, serum ferritin levels of patients with malignant melanoma were found to be increased in stage III of the disease. Therefore, serial determinations were carried out up to 24 months in patients at various stages of the disease...

...Thomas Luger; E.M. Kokoschka; P. Sagaster; Michael Micksche Serum lysozyme has been demonstrated to be an indicator for macrophage activity in the tumor-bearing host. Therefore, we investigated lysozyme levels in the sera of 336 untreated tumor patients (121 malignant melanoma, 61 lung cancers, 70...

...Gianni Beretta A review is made concerning the treatment of malignant melanoma. Medical therapies are at present applied in patients with metastatic disease, and also in surgically operated cases with high risk of recurrence. 10 6 2009 © 1980 S. Karger AG, Basel 1980 Copyright / Drug...

...G. Manelis; S.M. Shasha; J. Manelis; H. Suprun; E. Robinson The case of a 47-year-old white female patient has been described with malignant melanoma that started as a node on her right ankle twelve years ago and regressed spontaneously. During the last two years of her life, dissemination...

.... Malignant melanoma Immunological reactivity, Lymphokines Lymphocytes senzitization Tumorassociated antigens Electrophoretic-mobility-test Oncology 35: 163-167 (1978) Immunodiagnostics oi Malignant Disease VI. Electrophoretic Mobility Test (EMT) in Malignant Melanoma F. R. D o u w es; H. J. Spellmann...

...E.M. Kokoschka; C. Cerni; M. Micksche Patients in clinical stage I–III of malignant melanoma were treated after resection of the tumor mass with membrane extracts of autologous tumor tissue and BCG or BCG alone. They were monitored immunologically by delayed cutaneous hypersensitivity reactions...

...S. Biran; A. Hochman; N. Walach The clinical experience is described with 232 patients suffering from malignant melanoma. Various therapeutic procedures were applied, the largest group consisting of 82 patients treated by surgical excision followed by local irradiation. The next large group...

...J.A. Gottlieb; A.A. Serpick Thirty-one patients with malignant melanoma and 22 patients with other neoplasms were treated with intravenous 5-(3,3-dimethyl-triazeno) imidazole-4-carboxamide (DIC), utilizing 2 different regimens: a 5-day daily schedule of 150 to 300 mg/M 2 /day of DIC repeated every...

.... Malignant melanoma Pathogenesis Deleted in malignant brain tumours 1 (DMBT1) Loss of heterozygosity Reverse-transcription polymerase chain reaction Immunohistochemistry Malignant melanomas are one of the most aggressive skin cancers, and their incidence has dramatically increased over...

... was noted. It is con cluded that the CV-IL-IF regimen has limited activity and moderate toxicity. Malignant melanoma Biochemotherapy Interleukin-2 Interferon alpha-2a 12 12 1997 1997 Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may...